Nuo Therapeutics Q2 Revenue Jumps 150% as Losses Narrow; Loan Amended
AURX is trading near its 52-week low of $0.77 (0.0% above the low).
Summary
Nuo Therapeutics' Q2 revenue surged over 150% to $1.77M and operating losses narrowed sharply, while the company amended its loan for additional working capital.
Key Events · Earnings and Guidance · AURX
-
Q2 Revenue Up 150%
Total revenue reached $1.77 million in Q2 2026, up over 150% from $700K in Q2 2025, driven by strong Aurix product sales.
-
Operating Loss Narrows
Net operating loss improved to $167K from $447K in Q1 2026, a $280K sequential improvement, reflecting higher gross profit and controlled expenses.
-
Loan Amended with Interim Funding
The company amended its loan agreement, receiving $675K in interim funding with $325K remaining available under the $2M commitment, and holds an option to increase borrowings on September 30, 2026.
-
Reimbursement Milestone Achieved
Nuo confirmed achievement of a reimbursement fee milestone under the Smith+Nephew distribution agreement and expects payment this quarter.
Analysis · AURX · Industrial Applications And Services
Nuo Therapeutics reported Q2 2026 revenue of $1.77 million, up over 150% year-over-year, while net operating loss narrowed to $167,000 from $447,000 in Q1. The company also amended its loan agreement, securing $675,000 in interim funding with $325,000 still available, and confirmed a reimbursement milestone under its Smith+Nephew distribution deal. These results show accelerating commercial traction and improved cost control, but the company remains in a going-concern position with minimal cash reserves.
At the time of this filing, AURX was trading at $0.77 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $37.3M. The 52-week trading range was $0.77 to $3.23. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.